Aliskiren renin inhibitor

Description Results NMA

Aliskiren (n=1639)

vs.

placebo (n=0)

double blind

Parallel groups

Sample size: 1639/0

Primary endpoint: CV death or HF re-hospitalization

FU duration: 6 months

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

death 0.00 [0.00; NaN]

Any serious adverse event 0.95 [0.58; 1.58]

Any adverse event 0.99 [0.89; 1.11]

Discontinuation due to adverse event 0.89 [0.47; 1.67]

aliskiren (150 mg daily for 3 months, followed by an increase in dosage to 300 mg daily for another 3 months (n=301)

vs.

placebo (n=298)

double blind

Parallel groups

Sample size: 301/298

Primary endpoint: ratio of albumin to creatinine

FU duration: 6 months

death NaN [NaN; NaN]

Any serious adverse event 0.76 [0.34; 1.68]

Any adverse event 1.10 [0.90; 1.33]

Discontinuation due to adverse event 0.39 [0.13; 1.23]

aliskiren 300 mg (n=154)

vs.

losartan 100 mg (n=152)

3rd arms with combination

open

Parallel groups

Sample size: 154/152

Primary endpoint: LV mass index

FU duration: 9 months

aliskiren 150 mg (up to 300mg) daily (n=-9)

vs.

ramipril 5 mg (up to 10mg) daily (n=-9)

Dose titration (to aliskiren 300 mg/ramipril 10 mg) and subsequent hydrochlorothiazide addition (12.5 mg, titrated to 25 mg if required) were permitted at weeks 6, 12, 18 and 21 for inadequate blood pressure control

double blind

Parallel groups

Sample size: -9/-9

Primary endpoint: BP change

FU duration: 26 weeks

Any serious adverse event 1.17 [0.67; 2.03]

Any adverse event 1.06 [0.97; 1.16]

Discontinuation due to adverse event 0.70 [0.44; 1.11]

aliskiren 300 mg (n=567)

vs.

hydrochlorothiazide 25 mg (n=557)

double blind

Parallel groups

Sample size: 567/557

Primary endpoint: BP reduction

FU duration: 20 weeks